Study Shows Greater Clinical Improvement vs.\u00a0Metronidazole-Based Standard of Care with Favorable Tolerability<\/i> <\/p>\n
MIAMI BEACH, Fla.<\/span>, March 20, 2026<\/span> \/PRNewswire\/ —\u00a0Crescel LLC, an innovative science and technology company, today announced results from a\u00a0double-blind, randomized, active comparator-controlled clinical trial\u00a0evaluating its\u00a0biobotanical Skin Renewal Cream\u00a0compared to a commonly used standard of care\u2014topical metronidazole (Metrocream\u00ae<\/sup>) combined with CeraVe\u00ae<\/sup> moisturizer\u2014in individuals with rosacea, a chronic inflammatory skin condition.<\/p>\n The study, conducted under the direction of a\u00a0world-renowned dermatologist, enrolled 60 adult subjects with mild to severe rosacea and evaluated outcomes over a 12-week treatment period. Results from the trial are expected to be submitted for publication in a\u00a0peer-reviewed medical journal in 2026.<\/p>\n Clinical Outcomes<\/b> <\/p>\n Subjects were randomized to receive either Crescel Skin Renewal Cream or metronidazole 0.75% plus moisturizer twice daily. Dermatologist assessments were conducted at baseline and at Weeks 4, 8, and 12.<\/p>\n Crescel Skin Renewal Cream demonstrated\u00a0statistically significant improvements from baseline across key measures:<\/p>\n Both groups showed reductions in redness; however, the Crescel group demonstrated greater overall improvement. For inflammatory lesions, reductions observed in the comparator group did not reach statistical significance at any time point.<\/p>\n Tolerability<\/b> <\/p>\n Crescel Skin Renewal Cream was well tolerated, with\u00a0no negative side effects observed\u00a0during the study period. No clinically relevant issues related to irritation, dryness, or skin barrier disruption were reported.<\/p>\n Product Profile<\/b> <\/p>\n Crescel Skin Renewal Cream is formulated as a\u00a0biobotanical topical, combining naturally derived components with a proprietary microemulsion delivery system designed to support healthy skin function. The product has received the\u00a0National Rosacea Society Seal of Acceptance\u00a0and the\u00a0National Psoriasis Foundation Seal of Recognition.<\/p>\n “These findings support the potential for a new approach in managing rosacea,” said\u00a0Peter J. Passalacqua, Jr., Co-Founder, Chairman & CEO of Crescel. “In this controlled clinical trial, Crescel demonstrated greater improvement across key measures compared to a commonly used standard regimen, with a favorable tolerability profile.”<\/p>\n Additional Observations<\/b> <\/p>\n Crescel Skin Renewal Cream has also been evaluated in other skin-related conditions, including psoriasis, eczema, acne, and diabetic ulcers.<\/p>\n “Crescel’s healing capabilities are exceptional,” said\u00a0Dr. Roberta Shapiro, Department of Regenerative Medicine and Rehabilitation, Columbia University Medical Center and Senior Medical Advisor to Crescel. “I have never seen anything like this in my 30 years of practicing rehabilitation medicine.”<\/p>\n\n
\n
\n